Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q86YB8

UPID:
ERO1B_HUMAN

ALTERNATIVE NAMES:
Endoplasmic reticulum oxidoreductase beta; Endoplasmic reticulum oxidoreductin-1-like protein B; Oxidoreductin-1-L-beta

ALTERNATIVE UPACC:
Q86YB8; B4DF57; Q5T1H4; Q8IZ11; Q9NR62

BACKGROUND:
The ERO1-like protein beta, identified by its alternative names such as Endoplasmic reticulum oxidoreductin-1-like protein B, is pivotal in the oxidative folding process in the endoplasmic reticulum. It efficiently catalyzes the reoxidation of P4HB/PDI, enabling it to participate in further disulfide bond formation. This protein's activity is essential for the correct folding of proteins, including proinsulin, suggesting a significant role in glucose homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ERO1-like protein beta offers a promising avenue for developing novel therapeutic approaches, especially for metabolic disorders and diseases linked to protein misfolding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.